You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中金:首予歐康維視生物(1477.HK)跑贏行業評級 目標價38.5港元
格隆匯 06-24 12:49

中金公司發表研究報吿表示,首次覆蓋歐康維視生物(1477.HK)予跑贏行業投資評級,目標價38.5港元;並表示公司核心產品2021年開始產生收入,2025年扭虧為盈。

報吿指,中國眼科疾病普遍,但治療率低,市場供求失衡。據Frost&Sullivan統計,2019年中國各類眼科疾病的患病人數遠高於美國,但2019年中國眼科醫藥市場規模為28億美元,僅為同期美國的1/5。新藥方面,2015年至今共有7種眼科新藥獲NMPA(國家藥品監督管理局)批准在中國上市;但同期共有17種眼科新藥獲 FDA(美國國家藥品監督管理局)批准在美國上市,可見目前眼科市場仍然存在大量未滿足需求。

該行指,眼科醫藥行業專業化要求高,技術能力和創新要求共築准入壁壘。眼睛的構造複雜且精密,複雜性導致其具有多種疾病病變可能,精密性決定其對從業者的專業知識及技術能力要求也更高,所以認為專注眼科醫藥行業,經驗豐富,創新能力強,擁有較為豐富的產品管線的團隊在市場中具有競爭優勢。而歐康維視專注眼科醫藥市場,產品管線豐富。

截至2021年6月,公司通過獲得許可,收購或自主研發等方式,建立了18種眼科藥物組合,涵蓋眼前部及後部主要疾病,是中國少有的全面覆蓋眼科領域的公司之一。公司擁有FDA近年來批准的眼科新藥中大部分的中國權益以及自主研發的核心藥物,有望給現有治療方式帶來較大改變。該行預計未來公司將在產品的開發、引進,註冊、商業化及製造生產等多環節齊發力,搭建中國眼科藥物整體解決方案平台。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account